← 治験一覧に戻る
増殖性糖尿病網膜症に対するベバシズマブ硝子体内注射の前向き無作為化比較試験
基本情報
- NCT ID
- NCT01854593
- ステータス
- 完了
- 試験のフェーズ
- 第4相
- 試験タイプ
- 介入
- 目標被験者数
- 69
- 治験依頼者名
- Nihon University
概要
We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular tissue and whole body, intravitreal injection of a low concentration of bevacizumab and conducting vitrectomy shortly after the injection is useful. In the present prospective, double-masked, randomized, controlled study, we aimed to verify the usefulness of intravitreal injection of 0.16 mg/0.05 ml bevacizumab one day before conducting vitrectomy for PDR.
対象疾患
Proliferative Diabetic RetinopathyDiabetic Traction Retinal DetachmentVitreous Hemorrhage
介入
Bevacizumab(DRUG)
Vitrectomy(PROCEDURE)
Sham injection(DEVICE)
依頼者（Sponsor）
Nihon University(OTHER)
実施施設 (1)
日本大学病院
Tokyo, Japan